Anbio Biotechnology Presents Point-Of-Care IVD Solutions
Posted on 08 Feb 2024
Anbio Biotechnology (Frankfurt, Germany) is demonstrating its FIA, CLIA, LAMP, and dry chemistry analyzers, along with other easy-to-use diagnostic solutions, at Medlab Middle East 2024.
During the trade show, Anbio is showcasing its fluorescence immunoassay (FIA) solutions which include four types of analyzers, from portable handheld to bench-top sizes, as well as a wide range of assays. 78 available assays enable the detection of a variety of analytes, including hormones, cancer markers, cardiac markers, drugs of abuse, inflammation, and infectious diseases. Also on display is Anbio’s ADL i1910 chemiluminescence immunoassay analyzer which is designed to transform the landscape of clinical diagnostics. With an impressive range of 50 CE-marked assays, this fully automated, high throughput, compact CLIA analyzer supports both qualitative and quantitative testing of analytes.
At Medlab Middle East 2024, Anbio is presenting the SHA-100 small-sized, portable, and easy-to-use dry-chemistry analyzer that supports real-time testing and real-time printing of quantitative detection results for 18 test items. Anbio is also demonstrating its LAMP Solution, a diagnostic technique to amplify and detect specific DNA or RNA sequences that is used for various applications, including detecting infectious diseases, genetic disorders, and foodborne pathogens. Anbio’s LAMP solution offers miniaturized analyzers, which are extremely easy to use. The egg-shaped LAMP device is a one-button control capable of delivering fast, sensitive, and specific results for various infectious diseases. It is suitable for over-the-counter (OTC) and point-of-care (POC) diagnostics.
For the first time, Anbio is showcasing the ABO & Rhd Blood Grouping Kit, a qualitative detection test kit for the ABO and D antigen of the Rhd blood group system on human red blood cells in whole blood or 10% red cell suspensions in physiological saline. The ABO & Rhd Blood Grouping Kit is based on the principle of antigen-antibody dot immune filtration assay to provide convenience and accuracy in testing blood types for clinical use and emergencies. It can acquire accurate results from fresh fingertip blood in as little as one minute, with a storage time of 24 months, and does not require special refrigeration or cold-chain transportation. It can quickly display blood type information through paper strip reactions, representing a modern approach to blood type testing.
"Anbio is consistently dedicated to developing easy-to-access and reliable diagnostic test kits for improving user experience in various application scenarios," said Michael Lau, CEO of Anbio Biotechnology. "Anbio's ABO & Rhd Blood Grouping Kit provides a simple way for blood type testing with low requirements for user environment, storage, and transportation while ensuring the accuracy of the results. The target market of this product will be mainly focusing on the Middle East, Asia, and Africa regions. We will continue to invest in user-centric, affordable, and reliable Point-of-Care Testing solutions and bring them to the world."
Related Links:
Anbio Biotechnology
